The constitutive activation of the phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR) pathway has been documented in more than 40% of bladder cancers [86,87]. This evidence concerns the gene MTOR and urinary bladder cancer.